Rituxan (rituximab) - Roche
betamethasone microsphere (DE-102) - Santen
Monjuvi (tafasitamab-cxix) - Incyte
Mabtas (rituximab biosimilar) - Intas
Truxima (rituximab-abbs) - Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma (clinicaltrials.gov) - Oct 16, 2026 - P2 | N=30 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting 
Enrollment open • Follicular Lymphoma • Hematological Malignancies • Oncology
http://clinicaltrials.gov/ct2/show/NCT07731789
 
Oct 16, 2026
 
Prev Next